Avicanna Reports Full Year 2025 Audited Financial Statements

Avicanna Financial Highlights - positive adjusted EBITDA 2025

Achieved positive adjusted EBITDA in Q4 2025 and near break-even $(0.29) million for the full yearAdvancements across business units, R&D, and clinical development to support scale and international growth

Format

PNG

Source

Avicanna Inc.

Downloads